Servimed S.A.S.

Bucaramanga 680003

2 studies enrolling now · 17 studies all time

What they study most

Gout, Gout Flare, Hyperuricemia, Lupus Erythematosus, Systemic, Primary Sjogrens Disease, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Tophi

Studies at this site

• An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Enrolling by invitation
• Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus — Enrolling by invitation
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) — Running, not enrolling
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome — Stopped early
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Running, not enrolling
• A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus — Completed
• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) — Completed
• Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus — Stopped early
• A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus — Completed
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus — Completed
• Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care — Completed
• A Phase II Study of M2951 in SLE — Stopped early
• An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus — Stopped early
• Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis — Completed
• A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy — Stopped early